Pharmacological postconditioning: a molecular aspect in ischemic injury. (28th July 2020)

• Record Type: Journal Article
• Authors: Khan, Heena; Kashyap, Ankita; Kaur, Amarjot; Singh, Thakur Gurjeet
• Is Part Of: Journal of pharmacy and pharmacology. Volume 72:Number 11(2020)
• Page Start: 1513
• Page End: 1527
• Publication Date: 2020-07-28
• Subjects: ischemia/reperfusion injury -- pharmacological agents -- pharmacological postconditioning -- postconditioning -- signalling pathways; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.13336
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objective: Ischaemia/reperfusion (I/R) injury is defined as the damage to the tissue which is caused when blood supply returns to tissue after ischaemia. To protect the ischaemic tissue from irreversible injury, various protective agents have been studied but the benefits have not been clinically applicable due to monotargeting, low potency, late delivery or poor tolerability. Key Findings: Strategies involving preconditioning or postconditioning can address the issues related to the failure of protective therapies. In principle, postconditioning (PoCo) is clinically more applicable in the conditions in which there is unannounced ischaemic event. Moreover, PoCo is an attractive beneficial strategy as it can be induced rapidly at the onset of reperfusion via series of brief I/R cycles following a major ischaemic event or it can be induced in a delayed manner. Various pharmacological postconditioning (pPoCo) mechanisms have been investigated systematically. Using different animal models, most of the studies on pPoCo have been carried out preclinically. Summary: However, there is a need for the optimization of the clinical protocols to quicken pPoCo clinical translation for future studies. This review summarizes the involvement of various receptors and signalling pathways in the protective mechanisms of pPoCo.